Article Main

Association of Hepatitis B Virus Serological Markers with Glycemic Control and Diabetes Duration in Type 1 and Type 2 Diabetes Patients in the Najaf Government

Baneen Abdul Hadi Jalaout
Saif Jabbar Yasir
Journal of Progressive Medical Sciences, Vol. 1 No. 1 (2025): Journal of Progressive Medical Sciences
Published: 2025-05-31

Abstract

Background: Diabetes mellitus (DM) and hepatitis B virus (HBV) infection are two major global health concerns. Growing evidence suggests a possible association between chronic viral infections and glucose metabolism disorders. Objective: To investigate the association between HBV serological markers and glycemic control, as measured by fasting blood glucose levels and the duration of diabetes, among patients with type 1 and type 2 diabetes mellitus. Subjects and methods: A cross-sectional study was performed from July to October 2024. The serum was taken from 200 individuals. All of the patients were tested using an ELISA technique for HBc IgG and by an immunochromatographic assay for HBsAb, HBsAg, HBcAb, HBeAg, and HBeAb. The statistical analysis approach was conducted using SPSS version 26. Results: HBcAb-positive diabetic patients showed significantly higher fasting blood glucose levels (P=0.044). HBcIgG was detected in 83 out of 200 patients, mainly in those with 5–15 years of diabetes duration (P = 0.049). No significant association was found between HBV markers and diabetes type.Conclusions: a potential link between HBV exposure and impaired glycemic control , suggesting a possible role of chronic HBVexposure in the progression of metabolic dysfunction over time This suggests that the activation of a previous HBV infection may be an underlying factor in the progression of diabetes mellitus or the development of pre-existing conditions  and  the relationship between HBV and glycemic markers may be independent of diabetes type.

Keywords

Array Array Array Array Array

References

  1. 1. Arrelias CCA, Rodrigues FB, Torquato MTDCG, Teixeira CRS, Rodrigues FFL, Zanetti ML. 2018. Prevalence of serological markers for hepatitis and potential associated factors in patients with diabetes mellitus. Rev Lat Am Enfermagem. Nov 29;26: e3085.
  2. 2. Lazarevic, I., Banko, A., Miljanovic, D., & Cupic, M. (2023). Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas. Viruses. 15(2), 373.‏
  3. 3. Mirzaei M, Rahmaninan M, Mirzaei M, Nadjarzadeh A, Dehghani Tafti AA. (2020) Epidemiology of diabetes mellitus, pre-diabetes, undiagnosed and uncontrolled diabetes in Central Iran: results from Yazd health study. BMC Public Health. 20(1):166.
  4. 4. Gutiérrez-Grobe Y, Ponciano-Rodríguez G, MéndezSánchez N. 2017.Viral hepatitis infection and insulin resistance: a review of the pathophysiological mechanisms. Salud Publica Mex. [Internet]. 2011 [cited Jul 10, 2017]; 53Suppl1:S46-51.
  5. 5. Lu J, Hou X, Tu H, Tang Z, Xiang Y, Bao Y, et al. (2017). Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes. J Diabetes Investig. 8(4):619–625.
  6. 6. Schillie SF, Xing J, Murphy TV, Hu DJ. 2012. Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999-2010. J Viral Hepat 19(9):674-6.
  7. 7. Ndako JA, Nwankiti OO, Olorundare JO, Ojo SKS, Okolie CE, Olatinsu O, Dojumo VT. 2021.Studies on the serological markers for hepatitis B virus infection among type 2 diabetic patients. J Clin Lab Anal. Jan;35(1): e23464.
  8. 8. Saitta, C.; Pollicino, T.; Raimondo, G. (2022). Occult Hepatitis B Virus Infection: An Update, Viruses. 14(7), 1504.
  9. 9. Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, et al. (2019). Serum level of antibodies against Hepatitis B core protein is Associated with Clinical Relapse after discontinuation of Nucleos(t)ide Analogue Therapy. Clinical Gastroenterology and Hepatology, 17(1):182–191.
  10. 10. Tseng, C.H.; Hsu, Y.C.; Chang, C.Y.; Tseng, T.C.; Wu, M.S.; Lin, J.T.; et al. (2018). Quantification of serum hepatitis B core antibody topredict off-entecavir relapse in patients with chronic hepatitis B. J. Formos. Med. Assoc. 117(10), 915–921.
  11. 11. Guner R, Karahocagil M, Buyukberber M, Kandemir O, Ural O, Usluer G et al. 2011.Correlation between intrahepatic hepatitis B virus cccDNA levels and other activity markers in patients with HBeAg-negative chronic hepatitis B infection. Eur J Gastroenterol Hepatol. 23(12):1185-91.
  12. 12. Zhang H, Li Q, Sun J, et al. (2011). Seroprevalence and risk factors for hepatitis b infection in an adult population in Northeast China. Int J Med Sci,8(4):321‐331.
  13. 13. Caviglia, G. P., Olivero, A., Ciancio, A., Tandoi, F., Troshina, G., Rosso, C et al., (2020). Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagnostic Microbiology and Infectious Disease. 96(4), 114985.‏
  14. 14. Yan L, Zhang H, Ma H, Liu D, Li W, Kang Y, et al. (2015). Deep sequencing of hepatitis B virus basal core promoter and precore mutants in HBeAg-positive chronic hepatitis B patients. Sci Rep.5:17950. doi: 10.1038/srep17950.
  15. 15. Huang, J., Ou, Y., Lin, J., Karnchanasorn, R., Feng, W., Samoa, R., Chuang, M., & Chiu, K. C. (2015). The Impact of Hepatitis B Vaccination Status on the Risk of Diabetes, Implicating Diabetes Risk Reduction by Successful Vaccination. PLoS ONE, 10(10).
  16. 16. Zhang, H., Yang, Z., Zhang, W., Niu, Y., Li, X., Qin, L., & Su, Q. (2017). White blood cell subtypes and risk of type 2 diabetes. Journal of Diabetes and its Complications, 31(1), 31-37.
  17. 17. Cholongitas E, Haidich AB, Apostolidou-Kiouti, F, Chalevas P, Papatheodoridis GV. 2018. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. Jul-Aug;31(4):480-490.
  18. 18. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxi A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F (2008) Statements from the Taormina expert meeting on occult hepatitis B virüs infection. J Hepatol. 49:652–657
  19. 19. Raimondo, G.; Locarnini, S.; Pollicino, T.; Levrero, M.; Zoulim, F.; Lok, A.S.; et al. (2019). Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J. Hepatol. 71(2), 397–408.
  20. 20. Pollicino, T., and Caminiti, G. (2021). HBV-integration studies in the clinic: role in the natural history of infection. Viruses 13 (3), 368.
  21. 21. Sangiorgio L, Attardo T, Gangemi R, Rubino C, Barone M, Lunetta M.2000. Increased frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res Clin Pract. [Internet]. 2000 [cited Feb 11, 2017]; 48(2):147-51.
  22. 22. Wang C, Xue R, Wang X, Xiao L and Xian J (2023) High-sensitivity HBV DNA test for the diagnosis of occult HBV infection: commonly used but not reliable. Front. Cell. Infect. Microbiol. 13:1186877.
  23. 23. Gundling F, Seid H, Strassen I, Haller B, Siegmund T, Umgelter A, et al. (2013). Clinical manifestations and treatment options in patients with cirrhosis and diabetes mellitus. Digestion. 87(2):75-84.
  24. 24. Gutiérrez-Grobe Y, Ponciano-Rodríguez G, MéndezSánchez N. 2017.Viral hepatitis infection and insulin resistance: a review of the pathophysiological mechanisms. Salud Publica Mex. [Internet]. 2011 [cited Jul 10, 2017]; 53Suppl1:S46-51.
  25. 25. Lecube A, Hernández C, Genescà J, Simó R. 2006.Glucose abnormalities in patients with hepatitis C virus infection: epidemiology and pathogenesis. Diabetes Care.; 29(5):1140-9.
  26. 26. Berbudi, A., Rahmadika, N., Tjahjadi, A. I., & Ruslami, R. 2020. Type 2 Diabetes and its Impact on the Immune System. Current Diabetes Reviews, 16(5), 442-449.
  27. 27. Komatsu H. (2014). Hepatitis B virus: where do we stand and what is the next step for eradication? World J Gastroenterol. 20(27):8998.
  28. 28. Younossi, Z., Kochems, K., Curran, D., & Bunge, E. M. (2017). Should adults with diabetes mellitus be vaccinated against hepatitis B virus? A systematic review of diabetes mellitus and the progression of hepatitis B disease. Human Vaccines & Immunotherapeutics, 13(11), 2695-2706.
  29. 29. Han B, Liu W, Yang S, Wang S, Du J, Liu Y, Cui F. 2021.Association between self-monitoring of blood glucose and hepatitis B virus infection among people with diabetes mellitus: a cross-sectional study in Gansu Province, China. BMJ Open. Oct 7;11(10): e048463.
  30. 30. Lei S, Chen S, Zhao X, Zhang Y, Cheng K, Zhang X, et al. (2020). Hepatitis B virus infection and diabetes mellitus: the Kailuan prospective cohort study in China. Hepatol Int,14 (5):743–753.
  31. 31. Halota W, Muszyńska M, Pawłowska M. 2017. Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes. Med Sci Monit. [Internet]. 2002 [cited Nov 26, 2017]; 8(7):516-9.
  32. 32. Gulcan A, Gulcan E, Toker A, Bulut I, Akcan Y.2008. Evaluation of risk factors and seroprevalence of hepatitis B and C in diabetic patients in Kutahya, Turkey. J Investig Med; 56(6):858-63.
  33. 33. Onyekwere CA, Ogbera AO, Dada AO, Adeleye OO, Dosunmu AO, Akinbami AA, et al. 2016.Hepatitis C Virus (HCV) Prevalence in Special Populations and Associated Risk Factors: A Report from a Tertiary Hospital. Hepat Mon.16(5): e35532.
  34. 34. Kombi PK, Agasa SB, Mukonkole JPM, Bome LB, Bokele CA, Tshilumba CK. (2018) Seroprevalence of hepatitis B and C virus infections among diabetic patients in Kisangani (North-eastern Democratic Republic of Congo). Pan Afr Med J. Nov 2; 31:160.
  35. 35. Farshadpour, F., Taherkhani, R., & Saberi, F. (2022). Molecular evaluation of hepatitis B virus infection and predominant mutations of pre-core, basal core promoter and S regions in an Iranian population with type 2 diabetes mellitus: A case–control study. BMC Infectious Diseases, 22.
  36. 36. Cai C, Zeng J, Wu H, Shi R, Wei M, Gao Y, et al. (2015). Association between hepatitis B virus infection and diabetes mellitus: a meta-analysis. Exp Ther Med. 10(2):693–698.
  37. 37. Kaya, S. Y., & Kaya, A. (2020). Age Specific Hepatitis B Surface Antigen (HBsAg) and AntiHBs Seroprevalence among Patients Admitted to a State Hospital, Viral Hepatitis Journal ,26(2):85-87.

Author Biography

Baneen Abdul Hadi Jalaout
None
Saif Jabbar Yasir
None
PDF
Download PDF

Article Details

Most read articles by the same author(s)